Optimizing the sequence of targeted therapy in EGFR-mutant lung adenocarcinoma
EGFR-mutant lung cancers are highly sensitive to EGFR tyrosine kinase inhibitors (TKIs; erlotinib/gefitinib/afatinib), but tumors develop drug resistance within 9-16 months. Resistance to gefitinib/erlotinib commonly occurs via a second-site EGFR mutation, T790M. Two strategies to overcome T790M+ re...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | en |
| Published: |
VANDERBILT
2015
|
| Subjects: | |
| Online Access: | http://etd.library.vanderbilt.edu/available/etd-07202015-172236/ |